Since these data in PDAC strongly suggested that the secretion-associated MIA2 polymorphisms were associated with the clinical response to adjuvant chemotherapy, we sought to determine whether this was reflected in pancreatic cancer cell lines in vitro. The gene discussed is MIA2; the disease is familial pancreatic carcinoma.